Nasdaq
$19.85▲ 0.86%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $2.32BShares out 1.200M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
15- 10.2After-hours26.10.03 05:304Ownership#●●●
NewAmsterdam Pharma Co N.V.
Insider Johannes Jacob Pieter Kastelein of NewAmsterdam Pharma Co N.V. reported a change in beneficial ownership of securities as of September 30, 2026. This filing serves as an official notification to the SEC regarding the insider's equity transaction.…more
$19.85+0.86%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.29Pre-market26.09.29 21:228-KKey event
NewAmsterdam Pharma Co N.V.
NewAmsterdam Pharma announced the dosing of the first participant in the Phase 2b 'SPINOZA' clinical trial on September 29, 2026, to evaluate the efficacy and safety of obicetrapib in patients with preclinical Alzheimer's disease. The study will enroll approximately 400 participants for a 52-week treatment period, primarily measuring changes in blood-based biomarkers such as p-tau217.…more
$19.85+0.86%vs prev closeView filingShare - 9.22After-hours26.09.23 05:58SCHEDULE 13D/AOwnership
NewAmsterdam Pharma Co N.V.
Reporting persons FLSPF, FLS XI, and FLS XII consistently purchased ordinary shares of NewAmsterdam Pharma (NAMS) on the open market between September 8 and September 18, 2026. During this period, they acquired over 800,000 shares at weighted average prices ranging from $21 to $25, increasing their stake in the company.…more
$19.85+0.86%vs prev closeView filingShare
14 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.2After-hours26.10.03 05:01#●●●
NewAmsterdam Pharma Grants Equity Awards to New Hires
NewAmsterdam Pharma announced the grant of stock options and restricted stock units to seven new employees as an inducement for their hiring. This is a standard compensation practice for talent acquisition and is expected to have a neutral impact on the stock.…more
$19.85+0.86%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.29Pre-market26.09.29 21:00
●●●●●●●● ●●●●● ●●●●●●
NewAmsterdam Pharma has dosed the first participant in its Phase 2b SPINOZA trial evaluating obicetrapib for preclinical Alzheimer’s disease. The study aims to assess the drug's impact on disease-related biomarkers and cognitive measures in approximately 400 participants.…more
$19.85+0.86%vs prev close - 9.21Pre-market26.09.21 22:00
●●●●●●●● ●●●●● ●●●●●●
NewAmsterdam Pharma has received marketing authorization from the European Commission for its cholesterol-lowering drug, obicetrapib. This milestone enables commercialization in Europe through partner Menarini Group and triggers potential milestone payments.…more
$19.85+0.86%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report